The Abingdon Health PLC (LON: ABDX) share price surged 20% after launching Salistick™, the first-ever saliva pregnancy test, in the UK and Ireland. Salignostics Ltd, an Israeli developer of innovative saliva-based diagnostics tests, has developed the test.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.
Abingdon Health helped Salignostics develop the drug before offering its contract manufacturing services and is now helping it with the commercialisation efforts to provide distribution support. Investors cheered the news, as evidenced by the initial rally in Abingdon Health's share price.
Top Broker Recommendation
- eToro Top stock trading platform with 0% commission – Read our Review
- Admiral Markets More than 4500 stocks & ETFs available – Read our Review
- BlackBull 26,000+ Shares, Options, ETFs, Bonds, and other underlying assets – Read our Review
- IG Top-tier regulation – Read our Review
- XTB UK regulated by the FCA – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
Salistick™ offers women an improved user experience since they must apply a bit of saliva to the test to determine if they are pregnant. The tests allow women to use saliva for pregnancy tests instead of the traditional urine tests.
The novel pregnancy tests make it easier for women since they can be used anywhere, anytime, and the testing experience to be shared with a partner and other loved ones. Abingdon is the exclusive distributor of Salistick™ in the UK and Ireland on behalf of Salignostics Ltd.
Abingdon has launched Salistick™ by partnering with Superdrug, a leading health and beauty retailer in the United Kingdom. The test will be rolled out to 400 stores and sold online. Superdrug has over 900 stores across the United Kingdom and Ireland.
Furthermore, Salistick™ will also be launched through Abingdon's direct-to-consumer e-commerce channel Abingdon Simply Test. Salistick™ is co-branded Abingdon Simply Test™, with the Abingdon Simply Test™ range now including over 15 self-tests.
Abingdon is keen to keep expanding the range of innovative self-tests to make them available to consumers through partnering with companies such as Salignostics Ltd.
Abingdon Health plc’s CEO, Chris Yates, commented: “We are delighted to announce the launch of Salistick™ initially across 400 Superdrug stores and at Superdrug.com. This novel technology provides women with an enhanced user experience, offering the ability to test anywhere, anytime, and for the experience to be shared with a partner and other loved ones. We are pleased to have supported our partner Salignostics Ltd through the development process into manufacturing and now commercial launch, and we look forward to deepening our collaboration as we move forward.”
*This is not investment advice.
Abingdon Health share price.
The Abingdon Health share price surged 20% to trade at 18.00p, from Friday’s closing price of 15.00p.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.